23
Participants
Start Date
June 8, 2021
Primary Completion Date
December 7, 2023
Study Completion Date
January 30, 2024
HC-5404-FU
HC 5404-FU (hemi fumarate salt of HC 5404) is a novel, highly selective, and potent PERK inhibitor. Preclinical pharmacological studies demonstrated high specificity of HC 5404-FU to PERK and decreased viability of tumor cells. HC 5404-FU will be orally administered BID every day with food or within 30 minutes of completing a meal, starting at 25 mg, with doses escalating to 50, 100, 200, 400, 600, and 900 mg BID as safety allows for each 3-week treatment cycle.
Karmanos Cancer Institute, Detroit
HealthPartners Cancer Care Center, Saint Paul
Baylor University Medical Center, Dallas
The University of Texas M.D. Anderson Cancer Center, Houston
Lead Sponsor
Collaborators (1)
Covance
INDUSTRY
HiberCell, Inc.
INDUSTRY